Chemotherapy-induced anemia, gallbladder cancer, and immunotherapy management are important clinical challenges in oncology practice. In this video, Dr. Debashis Chatterjee, Consultant Oncologist at The Mission Hospital, Durgapur, presents a real-world case demonstrating the management of chemotherapy-induced anemia (CIA) in a patient with advanced carcinoma gallbladder receiving immuno-oncotherapy.The case discusses a 49-year-old female patient presenting with abdominal pain, gastrointestinal bleeding, and severe anemia. Through detailed clinical evaluation, imaging, and laboratory investigations, the patient was diagnosed with locally advanced carcinoma gallbladder with synchronous carcinoma sigmoid colon.Dr. Chatterjee explains the clinical decision-making process, treatment strategy, and supportive care approach used to manage anemia during active cancer therapy. The patient received Durvalumab-based immunotherapy along with chemotherapy agents Tegafur, Gemiracil, and Oteracil, supported by darbepoetin alfa to maintain hemoglobin levels and reduce the need for repeated transfusions.This case highlights the importance of integrating oncology treatment with supportive hematologic management, especially in patients receiving immunotherapy, where maintaining adequate hemoglobin levels is critical for treatment continuation and patient quality of life.Watch this video to understand:• Clinical presentation of advanced gallbladder cancer• Diagnostic approach and differential diagnosis• Challenges of chemotherapy-induced anemia• Role of erythropoiesis-stimulating agents in oncology• Strategies to support patients undergoing immuno-oncotherapy